Get the Stockscreener App
270.56
0.21%
-0.56
Ascendis Pharma A S stock is traded at $270.56, with a volume of 719.53K.
It is down -0.21% in the last 24 hours and up +10.62% over the past month.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
See More
Previous Close:
$271.12
Open:
$267.96
24h Volume:
719.53K
Relative Volume:
1.12
Market Cap:
$17.75B
Revenue:
$1.01B
Net Income/Loss:
$581.90M
P/E Ratio:
30.49
EPS:
8.8733
Net Cash Flow:
$50.57M
1W Performance:
+9.14%
1M Performance:
+10.62%
6M Performance:
+12.09%
1Y Performance:
+36.56%
1-Day Range:
$265.22
$271.14
1-Week Range:
$247.65
$272.44
52-Week Range:
$186.05
$282.15
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
270.56 | 16.71B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-17-25 | Initiated | Raymond James | Strong Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-05-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-16-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | UBS | Buy |
| Sep-05-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-25-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Initiated | Stifel | Buy |
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Stock (ASND) Latest News
Ascendis Pharma to Present Sentinel Cohort Data from reACHin Trial of TransCon CNP at ESPE 2026 - Quiver Quantitative
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 - GlobeNewswire
Ascendis Pharma (ASND) Could Be 14% Undervalued Following Yorvipath Reimbursement Progress - simplywall.st
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $312 - Moomoo
Ascendis Pharma (ASND) Reimbursement Win Puts Its Fair Value Narrative Back In Focus - finance.yahoo.com
Ascendis Pharma (ASND) Settles Patent Fight And Wins Canadian Yorvipath Reimbursement Backing - finance.yahoo.com
Ascendis Pharma Director Lars Holtug Executes Sale of 236 Shares at $264.13 Each - Kalkine Media
Stifel Nicolaus Remains a Buy on Ascendis Pharma (ASND) - The Globe and Mail
Ascendis Pharma (ASND) director to sell shares for taxes - Stock Titan
Oppenheimer Adjusts Price Target on Ascendis Pharma to $312 From $304, Maintains Outperform Rating - marketscreener.com
Ascendis Pharma A/S (ASND) Institutional Ownership 2026 - MarketBeat
Oppenheimer raises Ascendis Pharma stock price target on settlement By Investing.com - Investing.com Australia
BioMarin To Get Royalties From Ascendis Under IP Settlement - Law360
Oppenheimer raises Ascendis Pharma stock price target on settlement - Investing.com
BofA cuts Ascendis Pharma stock price target on settlement impact By Investing.com - Investing.com South Africa
BioMarin announces global settlement with Ascendis - The Pharma Letter
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Ascendis Pharma (ASND) Clears Yuviwel Patent Fight With Global Licensing Deal - simplywall.st
BofA cuts Ascendis Pharma stock price target on settlement impact - Investing.com
Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
Ascendis Pharma settles patent dispute with US-based Biomarin - medwatch.com
Ascendis Pharma ASND Draws Bullish Targets After Q2 Earnings Surge - timothysykes.com
Ascendis Pharma (NASDAQ: ASND) strikes global YUVIWEL settlement with BioMarin - Stock Titan
Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. Enter Binding Term Sheet for Global Settlement and License Agreement Related to Yuviwel and Navepegritide-Related Products - marketscreener.com
Ascendis to pay 20% Yuviwel royalties in patent settlement with BioMarin - Fierce Pharma
Why Ascendis Pharma (ASND) Stock Is Up Today - Quiver Quantitative
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis - BioSpace
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday - Benzinga
Jefferies lowers Ascendis Pharma stock price target on settlement - Investing.com
H.C. Wainwright reiterates Ascendis Pharma stock rating at buy By Investing.com - Investing.com Australia
Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - finance.yahoo.com
BioMarin Licenses CNP Program to Ascendis With 20%/18% Royalties, Ends Patent Disputes - TradingView
Ascendis agrees to pay BioMarin 20% of U.S. YUVIWEL net sales - Stock Titan
Ascendis Pharma A/S (ASND): Investor Outlook Reveals a Promising 27% Upside Potential in Biotech - DirectorsTalk Interviews
BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea - PR Newswire
Ascendis Pharma (ASND) Shares Week 104 Data As FDA Clears Pediatric Achondroplasia Drug - simplywall.st
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Ascendis Pharma stock coverage with buy rating By Investing.com - Investing.com India
This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Ascendis Announces Oral Presentation of Week 104 Data from - GlobeNewswire
Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside - simplywall.st
Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 23.63% Potential Upside - DirectorsTalk Interviews
Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine - Yahoo Finance
Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript - AOL.com
Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress? - Yahoo Finance
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets - MarketBeat
Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced? - Yahoo Finance
Price to earnings forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Ascendis a new outperform at BMO on TransCon platform growth - Seeking Alpha
Penn Series Small Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus
BMO initiates Ascendis Pharma stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Ascendis Pharma A S Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):